ArticleRevista medica del Instituto Mexicano del Seguro Social2024
[Partial trisomy 9p syndrome: Expanding the phenotype].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trisomy of the short arm of chromosome 9 (9p) is the fourth most common chromosomopathy. It is a partial or complete autosomal structural anomaly of the short arm of chromosome 9. It is generally caused by a reciprocal parental translocation between chromosome 9 and another autosome; spontaneous genetic alteration (de novo) is rare. It presents great phenotypic variability due to the variable size of the chromosome fragment involved. Clinical case: We present the case of a patient diagnosed with trisomy of the short arm of chromosome 9 with a karyotype with a chromosomal complement 46,XX,add(9)(p24), interpreted as an additional chromosome fragment on chromosome 9p. A microarray study was carried out, which reported that the 9p24.3-p13.1 region is found in triple dose, which corresponds to a partial trisomy 9p or Rethoré syndrome, which is a low prevalence entity, with an expressiveness and variable prognosis. In the present case, the finding of a murmur and diagnosis of pulmonary valve stenosis was the initial approach; The heart disease described in our patient has not been reported in the literature as part of the clinical picture, meaning that it was not an initial diagnostic suspicion. Conclusion: Despite having described an already defined phenotype, other clinical data that are not documented should be considered, and when new clinical evidence is found, report it and thereby expand the phenotype for a timely diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.